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ABSTRACT 
 
Background: Patients may need massive volume-replacement therapy 
after cardiac surgery because of large fluid transfer perioperatively. 
Cardiopulmonary
 
bypass (CPB) also elevates the risk for bleeding. Af-
ter cardiac surgery, hemodynamic stability is better maintained with 
colloids than with crystalloids when a similar volume of fluid is given. 
However, colloids have more adverse effects such as coagulation dis-
turbances and impairment of renal function than do crystalloids.  
     The present study examined the effects of modern hydroxyethyl 
starch (HES) and gelatin solutions on blood coagulation and hemody-
namics. The mechanism by which colloids disturb blood coagulation 
was investigated by modified thromboelastometry (TEM) after cardiac 
surgery, and in vitro by use of experimental hemodilution.  
Materials and methods: Ninety patients scheduled for elective pri-
mary cardiac surgery (Studies I, II, IV, V), and twelve healthy volun-
teers (Study III) were included in this study. The patients had pre-
served left ventricle function preoperatively and had neither coagula-
tion disturbances nor renal nor liver failure. During surgery, Ringer’s 
acetate solution was given for volume replacement. After admission to 
the cardiac surgical intensive care unit (ICU), patients were rando-
mized to receive either 15 mL kg
-1 
of 
 
HES 130/0.4, HES 200/0.5, or 
4% albumin solution (Studies I, IV). The effect of cumulative doses of 
7 mL kg
-1
, 14 mL kg
-1
, 21 mL kg
-1
, and 28 mL kg
-1 
of
 
HES 130/0.4 or 
4% gelatin solution was compared to that of Ringer’s acetate (Studies 
II, V). 
     To explore in more detail the mechanisms by which colloids dis-
turb coagulation, venous blood collected from twelve healthy volun-
teers was diluted by gelatin in vitro. Thereafter, single coagulation 
factor concentrates (coagulation factors VIII+von Willebrand factor 
(FVIII+vW), coagulation factor XIII (FXIII), and fibrinogen, as well 
as fresh frozen plasma (FFP) were added to diluted samples. 
     Coagulation was assessed by TEM, and hemodynamic measure-
ments were based on pulmonary artery pressures and thermodilution-
ally measured cardiac index (CI).  
ABSTRACT 
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Results: HES 130/0.4 and HES 200/0.5, as well as gelatin solutions 
impaired whole blood coagulation similarly as measured by TEM 
(Studies I, II) even at a small dose of 7 mL kg
-1
. These solutions re-
duced clot strength and prolonged clot formation time (CFT), and 
these effects were more pronounced with increasing doses of colloids 
(Study II). The albumin solution did not disturb whole blood coagula-
tion after cardiac surgery. Ringer’s acetate enhanced coagulation by 
increasing clot strength slightly after a relatively large cumulative 
dose (14 mL kg
-1 
or more). Fibrinogen concentrate, but neither 
FVIII+vW nor FXIII improved clot strength after gelatin hemodilution 
in vitro (Study III).  
     Coagulation disturbance after infusion of HES 130/0.4, HES 
200/0.5, or gelatin solutions was clinically slight, and postoperative 
blood loss was comparable with that of Ringer’s acetate or albumin 
solutions. 
     Both single dose (Study IV) and multiple dose (Study V) of all the 
colloids increased CI and stroke volume index (SVI) postoperatively, 
and this effect was dose-dependent in Study V. Ringer’s acetate had 
no effect on CI or SVI (Study V). On the first postoperative morning, 
CI and SVI were similar in all the study groups, but higher than before 
the infusion of study solution. The hemodynamic effect of HES 
130/0.4 was similar to that of the HES 200/0.5 solution, but more pro-
nounced than that of albumin (Study IV). At a small dose (7 mL kg
-1
), 
the effect of gelatin on CI and SVI was comparable with that of Rin-
ger’s acetate solution and significantly less than that of HES 130/0.4 
(Study V). However, when the dose was increased to 14 and 21 mL 
kg
-1
, the hemodynamic effect of gelatin rose and became comparable 
to that of HES 130/0.4. 
     After infusion of gelatin solution, the strong ion difference (SID) 
was greater than after infusion of HES 130/0.4 or Ringer’s acetate so-
lutions. However, there were no differences in acid-base equilibrium 
between the HES 130/0.4, gelatin, or Ringer’s acetate groups.  
Conclusions: In cardiac-surgery patients postoperatively, HES and 
gelatin solutions impaired clot strength in a dose-dependent manner.  
The potential mechanisms were interaction with fibrinogen and fibrin 
formation, resulting in decreased clot strength, and hemodilution. 
ABSTRACT 
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     Although the use of HES 130/0.4, of HES 200/0.5, or of gelatin in-
hibited coagulation, postoperative bleeding after elective cardiac sur-
gery was not higher than for albumin and Ringer’s acetate. Chest tube 
drainage on the first postoperative morning in all the study groups was 
similar.   
     A single dose of HES 130/0.4 and HES 200/0.5 solutions improved 
CI and SVI postoperatively more than did gelatin, albumin, or Rin-
ger’s acetate. However, when administered in a repeated fashion, 
(cumulative dose of 14 mL kg
-1 
or more), no differences were evident 
between HES 130/0.4 and gelatin. On the first postoperative morning, 
CI and SVI in all study groups were similar. 
     The study solutions caused no clinically significant changes in ac-
id-base equilibrium postoperatively. 
 
INTRODUCTION 
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INTRODUCTION 
 
     After major surgery, colloid solutions (HES, gelatin, albumin, dex-
tran) ensure volume resuscitation. Because of good volume expansion 
capacity, colloids are recommended in partial replacement of the 
blood loss. On the other hand, colloid solutions have led to impaired 
blood coagulation, therefore aggravating risk for postoperative bleed-
ing. Both clinical and experimental studies have shown that HES solu-
tions reduce clot strength as assessed by whole blood coagulation 
analysis (i.e., TEM). These effects depend on the molecular weight 
(MW), degree of substitution, and the C2:C6 ratio of HES solutions. 
High-MW HES solutions cause increased bleeding after cardiac sur-
gery (Cope et al. 1997). The impact of rapidly degradable HES solu-
tions of low MW (i.e., HES 130/0.4) on postoperative blood loss is 
minimal or absent (Van der Linden et al. 2005), although laboratory 
analysis has revealed some negative effects (Felfernig et al. 2003). 
The effect of gelatin on blood coagulation is controversial. It has been 
suggested that the effect of gelatin on hemostasis is less than that of 
HES, probably due to the low MW of gelatin (30 kDa). After cardiac 
surgery, a gelatin solution has impaired blood coagulation to a similar 
extent as that of HES (Niemi et al. 2006), and reduced platelet aggre-
gation (Boldt et al. 1992). 
     Crystalloid solutions do not impair blood coagulation more than 
hemodilution could explain, but their volume expansion effect is less 
than that of colloids. After major surgery, maintenance of an adequate 
preload requires a volume of crystalloids double or more than that of 
colloids (Lang et al. 2001). Thus, risk for tissue edema and risk for an 
increased amount of extravascular lung water can rise, as has occurred 
in critically ill patients (Vrancken et al. 2005). 
     After CPB, patients are predisposed to bleeding complications be-
cause CPB induces platelet dysfunction, reduces the amount of coagu-
lation factors, and promotes fibrinolysis (Parolari et al. 2003). Hemo-
dilution and hypothermia as well as the use of heparin also have de-
trimental effects on blood coagulation.           
     The main indication for colloids after cardiac surgery is to stabilize 
intravascular volume and maintain hemodynamics. The study of Kui-
tunen and co-workers (2007) showed that after cardiac surgery, the ef-
INTRODUCTION 
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fect of gelatin on cardiac output (CO) and oxygen delivery (DO2) is 
inferior to that of HES 200/0.5.  
     No evidence exists of benefit to patients’ outcome with regard to 
different types of colloid or crystalloid solutions (Perel and Roberts 
2007). However, the clinical effects of various colloids are dissimilar: 
blood coagulation, hemodynamics, and kidney dysfunction are related 
to the type of colloid given. Especially after cardiac surgery, the cha-
racteristics of the colloid solution are of clinical importance. The ideal 
colloid must improve hemodynamics rapidly, without disturbing blood 
coagulation or leading to increased postoperative risk for bleeding.  
     The objective of the present study was to compare several modern 
colloid solutions (i.e., HES 130/0.4, HES 200/0.5, and gelatin) after 
elective cardiac surgery and assess their effects on coagulation and 
hemodynamics. 
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REVIEW OF THE LITERATURE 
 
1. Principles of volume replacement therapy after 
major surgery 
       During cardiac surgery with CPB, homeostasis is affected because 
of fluid therapy, CPB-related coagulation disturbances, perioperative 
bleeding, hypothermia, and mechanical ventilation. Administration of 
fluids aims not only to stabilize macrohemodynamics, but also to in-
duce beneficial effects on microcirculation and tissue oxygenation 
(Lang et al. 2001). 
     According to the current concept, any deficit in circulating plasma 
should be replaced with a colloid, and this infusion of colloid should 
be guided by goal-directed methods (Chappell et al. 2008, Hiltebrand 
et al. 2009). 
     Many controversies continue in regard to the quantity and quality 
of fluids appropriate for postoperative plasma volume expansion. Re-
cent findings have changed the principles of volume replacement ther-
apy in patients undergoing surgery. Research work in physiology has 
shown the important role of the endothelial glycocalix (Levick and 
Michel 2010) in inhibiting fluid shift from intravascular into the in-
terstitial space. The glycocalix is a physiological barrier between the 
microcirculatory vessel (arteriole, capillary) wall and the interstitial 
space (Rehm et al. 2004). Preventing damage to the endothelial glyco-
calix should therefore minimize fluid shifting and tissue edema.  
     Some studies have shown that the fluid overload during and after 
surgery may prove harmful (Brandstrup et al. 2003), even fatal. Lo-
well and co-workers (1990) demonstrated that after major surgery 
those patients with a body weight increase of over 20% died, but a 
moderate fluid overload postoperatively could improve the DO2 (Ar-
kilic et al. 2003) as well as the microcirculation in critically ill pa-
tients (Lang et al. 2003). Nevertheless, many studies report a better 
physiological outcome using the optimal model of volume replace-
ment (Tølløfsrud et al. 1995, Lobo et al. 2002, Brandstrup et al. 2003, 
Nisanevich et al. 2005).  
     The Cochrane library meta-analysis could not show that outcome 
after surgery or in critically ill patients can be modified by administra-
REVIEW OF THE LITERATURE 
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tion of different types of fluids (Perel and Roberts 2007). However, 
many investigators have shown that colloid solutions improve hemo-
dynamics better than do crystalloids in animal experiments (Su et al. 
2007), in septic patients (Huang et al. 2009), and after cardiac or ma-
jor vascular surgery (Karanko et al. 1987, Verheij et al. 2006a). Some 
studies show body weight gain and extravascular lung water to be in-
creased through the use of crystalloid solutions (Huang et al. 2009), 
and after major surgery, this fluid overload can prolong the ICU stay 
(Gan et al. 2002). One study in septic patients showed also that the 
fluid overload which occurs within a few days requires some weeks to 
resolve (Cheng et al. 1998).  
     After cardiac surgery, intravenous fluid administration has received 
wide attention (Karanko et al. 1987, Kuitunen et al. 2007, Boldt et al. 
2007, 2008). After open heart surgery, postoperative volume replace-
ment is challenging and should be guided individually by each pa-
tient’s requirements. Patients need adequate fluid therapy to create an 
optimal preload and maximize tissue perfusion. Decreased intravascu-
lar volume after open cardiac surgery can result in low-output syn-
drome and hypoperfusion of the tissues. On the other hand, fluid over-
load causes tissue edema, which may have negative effects on out-
come (Brandstrup et al. 2003). The goal-directed use of colloids, crys-
talloids, and blood products, as needed, is the basis of modern fluid 
therapy (Gan et al. 2002, Boldt 2007).  
 
2. Colloid solutions 
 
2.1 Hydroxyethyl starches 
     Natural starches cannot serve as plasma substitutes because they 
are rapidly degradable by circulating amylase, and they are insoluble 
at a neutral pH. HES solutions are widely used colloids in cardiac sur-
gery patients, with new HES solutions being developed rapidly. HESs 
are polymers of glucose units derived from amylopectin with substitu-
tion of hydroxyl by hydroxyethyl groups on glucose molecules. HES 
solutions are polydisperse, and their in vitro MW ranges from a few 
kilodaltons (kDa) to several hundred. After administration of HES, the 
low-MW fraction (< 70 kDa) is removed rapidly by renal elimination, 
and the large molecules are progressively hydrolyzed, resulting in an 
REVIEW OF THE LITERATURE 
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average in vivo MW which is lower than the MW of the infused fluid. 
The degradation of HES molecules depends on the degree of substitu-
tion, which is the proportion of glucose units having a hydroxyethyl 
group instead of a hydroxyl group. A high degree of substitution re-
sults in slower degradation and increased solubility (Treib et al. 1996).  
     The currently available HES solutions have a degree of substitution 
between 0.4 and 0.7. According to the degree of substitution, HES so-
lutions are divided into tetra- (degree of substitution = 0.4), penta- 
(degree of substitution = 0.5), hexa- (degree of substitution = 0.6), and 
hetastarches (degree of substitution = 0.7). Because substitution is 
possible at positions 2, 3, or 6 of the glucose unit, different patterns of 
substitution are possible. The substitution pattern is characterized by 
the C2:C6 hydroxyethylation ratio. Clearance of HES is slowest with 
high C2:C6 ratios (Westphal et al. 2009). HES solutions are therefore 
classified by their initial MW, degree of substitution, and C2:C6 ratio 
(de Jonge et al. 2001). Usually, HES molecules are mixed with normal 
saline, but recently HES solutions have also been available in their ba-
lanced form (electrolyte concentrations corresponding to those of 
plasma). 
     The further development of HES started from the high MW (400-
600 kDa) solutions with a high degree of substitution 0.6-0.7 (slowly 
degradable HES solutions) (Fig. 1), which has been demonstrated to 
impair blood coagulation (Felfernig et al. 2003) and renal function 
(Schortgen et al. 2001). In 1999, the rapidly degradable tetrastarch 
with a MW of 130 kDa was synthesized (“third generation” HES).  
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Figure 1. Development of HES solutions.  
 
 
2.1.1. Coagulation effects of hydroxyethyl starches 
 
     Discussion is continuous as to the safety of HES solutions regard-
ing blood coagulation. The first reports of negative effects of high-
MW HES solutions on blood coagulation were published in 1965 
(Thompson and Gadsden). The possible mechanisms have been wide-
ly studied in experimental (Hiippala 1995, Nielsen 2005) and clinical 
studies (Langeron et al. 2001, Boldt et al. 2002). Large HES mole-
cules interfere with fibrinogen, coagulation factor VIII, and von Wil-
lebrand factor, and their negligible effect on coagulation is more than 
can be expected as a result of hemodilution (Omar et al. 1999). HES 
also promotes platelet dysfunction by disturbing platelet aggregation 
in vitro (Boldt et al. 1993). In studies assessing viscoelastic properties 
of whole blood, HES has been consistently demonstrated to disturb fi-
brin formation and to reduce clot firmness (Niemi and Kuitunen 1998, 
Boldt et al. 2007). The resulting thrombus is therefore less stable and 
more susceptible to lysis (Nielsen 2006). After these findings it was 
not surprising that even slight coagulation disorders were considered 
as a contraindication for the use of hetastarches.  
     Rapidly degradable HES solutions such as tetrastarch HES 130/0.4 
have good plasma-expanding capacity and good hemodynamic effects 
without clinically significant impairment of blood coagulation after 
6% HES 450/0.7    
3%, 6%, 10% HES 70-
260/0.45-0.62    
6% HES 130/0.4    
balanced 6% HES 550/0.75    
balanced 6% HES 130/0.4    
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cardiac surgery (Gallandat Huet et al. 2000, Kuitunen et al. 2004, 
Boldt et al. 2008), or in critically ill patients (Palumbo et al. 2006).  
     In 2001, Wilkes and co-workers published a meta-analysis of ran-
domized studies in cardiac surgery: the average 24-hour postoperative 
blood loss after cardiac surgery was 96 mL greater after use of HES 
solutions than after albumin, which was significantly higher. That par-
ticular meta-analysis included HES solutions with a MW of 200 to 
400 kDa and a degree of substitution of 0.5 to 0.7. They had been ad-
ministered both intra- and postoperatively. The recent pooled analysis 
of randomized trials (Kozek-Langenecker et al. 2008) showed that 
blood loss in patients undergoing major surgery and receiving HES 
130/0.4 solution was less than in patients who received HES 200/0.5. 
 
2.1.2 Hemodynamic effects of hydroxyethyl starches 
 
       Many studies have demonstrated the successful use of HES solu-
tions in maintaining hemodynamic goals after different types of sur-
gery, and in critically ill patients (Boldt et al. 1996, Lang et al. 2003, 
Kuitunen et al. 2007). HES solutions have a good plasma-expansive 
property, which lasts several hours. The volume-expansion effect is 
dependent on the degree of the volume deficit before the administra-
tion of the HES solution, as well as the concentration and MW of the 
HES. Usually, in hypovolemic patients the plasma-expansion effect of 
HES is about 100% (Zaar et al. 2009), but actually it is individual and 
can range from 70 to 220% (Kröll et al. 1993). The MW of the HES 
molecule plays a big role in the volume replacement. Because of their 
relatively high MW (70 to 670 kDa), HES molecules do not shift 
through the endothelium as do colloids with low MW (<70 kDa), or as 
do crystalloids, and they can remain in the intravascular space. Degree 
of tissue edema is therefore less than with the use of crystalloids 
(Lang et al. 2001).  
     Actually, it is unclear whether various HES solutions have equal 
hemodynamic effects. A few studies have compared different HES so-
lutions in some specific situations (trauma, major orthopedics), but the 
results are still discordant (Langeron et al. 2001, Persson and Grande 
2006). 
     The hemodynamic effects of HES solutions have also been com-
pared with those of other types of fluids. Some trials have reported 
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that HES is superior to albumin or gelatin solutions (Palumbo et al. 
2006, Kuitunen et al. 2007). In an experimental model of hemorrhagic 
shock, the hemodynamic effect was better with HES than with crystal-
loid solutions (Persson and Grande 2005). The amount of crystalloid 
needed to maintain similar hemodynamics was greater than that of 
HES (Lang et al. 2001). On the other hand, some studies found no dif-
ference in volume efficacy with different colloid solutions (Moggio et 
al. 1983, Beyer et al. 1997).   
       
2.1.3 Other effects of hydroxyethyl starches 
 
     One of the clinically important side-effects of HES solutions is 
their possible adverse effect on renal function. In 2008, the multicen-
ter randomized study showed that use of HES 200/0.5 in septic pa-
tients was worse for renal function than was Ringer’s solution 
(Brunkhorst et al. 2008). However, in sub-group analysis, mortality 
was lowest in the group of patients administered the recommended 
dose of HES 200/0.5 (<22 mL kg
-1
) (31%) in comparison with patients 
administered Ringer’s (41%) or a high dose of HES (58%) solutions. 
That study was criticized for using high doses of pentastarch HES 
200/0.5 in the treatment of patients with already evident renal dys-
function (exclusion criteria: serum creatinine over 320 µmol L
-1
).  
     The renal effects of HES 130/0.4 have also been studied. Those 
relatively small studies which include 20 to 25 patients per group 
demonstrated that this solution did not impair renal function after ma-
jor vascular surgery (Mahmood et al. 2007). Even in patients with 
previous renal dysfunction, serum creatinine, glomerular filtration 
rate, and cystatin C plasma levels as well as urine output were compa-
rable between HES and albumin groups after cardiac surgery (Boldt et 
al. 2007). Boldt and co-workers (2004) demonstrated also that after 
cardiac surgery the effect of HES 130/0.4 on endothelial inflammatory 
response was better than that of gelatin.   
     The use of the “first-” and “second generation” HES solutions was 
associated with accumulation of high-MW HES molecules in different 
tissues. Because of this, the repeated administration of HES was re-
garded as contraindicated in patients with renal or liver failure. The 
prolonged persistence of HES in plasma and tissues can be avoided by 
use of rapidly degradable HES solutions with degree of substitution 
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<0.5 (tetrastarches) (Jungheinrich and Neff 2005). Waitzinger and co-
workers (2003) showed that even the use of repeated doses of HES 
130/0.4 caused no accumulation in the plasma of human volunteers. 
Accumulation of tetrastarches in the tissues has not been studied. 
    Although allergic reactions are possible in patients receiving HES 
solutions, such reactions after administration of tetrastarches occurred 
in only 0.05%, less than after a gelatin solution (Dieterich et al. 1998).  
 
2.2 Gelatin 
     Gelatins are polydisperse polypeptides produced by degradation of 
bovine collagen. Two separate forms are available: succinylated (mod-
ified) gelatins, or polygelatins. Modified gelatins have their ammo-
nium groups replaced by acetate groups due to reaction of the basic 
peptide with succinic acid anhydrase; polygelatins consist of polypep-
tides cross-linked by urea bonds. Gelatins are widely used in some 
countries for plasma volume replacement because they are considered 
to have no adverse effects on renal function or blood coagulation 
(Haisch et al. 2001, Schortgen et al. 2001). Gelatin maintains intra-
vascular volume better and causes less tissue edema than crystalloids 
do (Van der Heijden et al. 2009).  
     In Scandinavia the use in ICUs of HES 130/0.4 is greatest in com-
parison with other colloids (60%). The use of gelatin has decreased to 
less than 5%, and in 2008 it was comparable to that of dextrans or al-
bumin (Perner et al. 2008).       
 
2.2.1 Coagulation effects of gelatin 
 
     Gelatin solutions
 
disturb the reticular fibrin mesh and reduce func-
tional clot
 
quality in vitro (Mardel et al. 1998), making the clot less 
stable and more sensitive to lysis in comparison to an intact clot. Gela-
tin impairs blood coagulation in experimental studies (de Jonge et al. 
1998, Niemi and Kuitunen 2005), and the effect of gelatin on blood 
coagulation is comparable to that of tetrastarches, according to mod-
ified TEM (Fries et al. 2006). In in vitro conditions, gelatin impairs 
blood coagulation less than hetastarches do (Petroianu et al. 2000). 
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     Several clinical studies have reported similar blood loss and use of 
blood products after infusion of gelatin or HES 130/0.4 solutions after 
cardiac surgery (Van der Linden et al. 2005, Niemi et al. 2006). The 
effect of gelatin is slight, without any evidence of increased blood loss 
perioperatively. However, Niemi and co-workers (2006) demonstrated 
that the clot quality in TEM correlates with postoperative bleeding.     
      
2.2.2 Hemodynamic effects of gelatin 
 
     The plasma volume expansion effect of gelatin, lasting 2 to 4 
hours, is relatively short. Because of its rapid metabolism without tis-
sue accumulation (MW of 30 kDa), gelatin has served perioperatively 
for volume replacement. 
     The capacity of gelatin to maintain hemodynamics has been stu-
died in experimental and clinical investigations (Marx et al. 2002, 
Verheij et al. 2006b). Kröll and co-workers had already shown in 
1993 that the volume expansion effect of 500 mL of gelatin in healthy 
volunteers is significantly inferior to that of HES and even shorter 
than that of crystalloid solution (Ringer).  
     Su and co-workers (2007) showed in an animal model of septic 
shock that the volume effect of gelatin is superior to that of crystallo-
ids, and this study demonstrated also that the effect of HES is better 
then that of gelatin solutions.  
     When gelatin has been compared with HES solutions, clinical stu-
dies show conflicting results. In some studies after cardiac surgery, 
gelatin has improved CI and mixed venous saturation (SvO2) as effec-
tively as HES solutions did (Van der Linden et al. 2004). On the other 
hand, Kuitunen and co-workers (2007) showed that the hemodynamic 
effect (as monitored by CI and SVI) of a single dose of pentastarch 
was better and lasted longer than that of gelatin.  
         
2.2.3 Other effects of gelatin 
 
     No recommendation exists for maximal daily dose of gelatin. It has 
been safely used for plasma volume replacement in critically ill pa-
tients with less effect on renal function than with HES (Schortgen et 
al. 2001). In a multicenter randomized study by this group, when gela-
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tin or hexastarch with a MW of 200 kDa was administered to septic 
patients, the gelatin induced significantly lower peak creatinine con-
centrations and a lower frequency of renal failure than did hexastarch 
in patients with septic shock. However, other investigators have re-
ported the opposite findings. After cardiac and major vascular surgery, 
serum creatinine and α-1 microglobulin were higher, and creatinine 
clearance and glomerular filtration lower after use of gelatin than after 
tetrastarch (Mahmood et al. 2007, Boldt et al. 2008).  
     The frequency of allergic reactions with gelatin solution (0.35%) is 
more than six-fold that with HES (Laxenaire et al. 1994).  
 
2.3 Albumin 
     Before 1990, the use of albumin as a colloid solution was domi-
nant. In 1990, the Transfusion Practices Committee of the American 
Association of Blood Banks recommended minimizing the use of al-
bumin for plasma volume replacement. Their reason was that synthet-
ic crystalloid or colloid solutions lack the potential to transmit infec-
tion (Goodnough et al. 1990). Even in Finland with its low infection 
risk after transfusions, the use of albumin continues to decrease. In 
2004, results of the SAFE (The Saline versus Albumin Fluid Evalua-
tion) study showed that albumin has no effect on mortality in critically 
ill patients in comparison with normal saline (Finfer et al. 2004).  
 
2.3.1 Coagulation effects of albumin 
 
     Albumin solutions do not impair clot strength, a fact important for 
the treatment of patients after cardiac surgery (Kirklin et al. 1984). In 
comparison with HES and gelatin solutions, albumin causes no 
changes in TEM (Niemi et al. 2006). One study showed slight hypo-
coagulation after albumin transfusion, probably because of its hemodi-
lution effect (Tobias et al. 1998). 
 
2.3.2 Hemodynamic effects of albumin 
 
     Several studies have demonstrated stable hemodynamics to be as-
sociated with the use of albumin in experimental (Persson and Grande 
2005) and clinical studies (Karanko et al. 1987, Kuitunen et al. 2007). 
In comparison with synthetic colloids, no differences were observable 
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in cardiac performance after the postoperative administration of HES 
or albumin solutions (Moggio et al. 1983, Kirklin et al. 1984, London 
et al. 1989, Mastroianni et al. 1994). However, the rapidly degradable 
HES solutions are considered to have an effect on hemodynamics 
more favorable than that of albumin in critically ill patients (Boldt et 
al. 1996, 1998, Palumbo et al. 2006). In the short term, however, al-
bumin has superior resuscitation capacity (i.e., correction of CO, 
blood lactate, and pH) when compared with the capacity of HES solu-
tions in studies on animals (Walcher et al. 1996, Cabrales et al. 2005).  
 
2.3.3 Other effects of albumin 
 
     Albumin has been shown to induce mild metabolic acidosis in pa-
tients undergoing normovolemic hemodilution during surgery, a 
process explained by the changes in SID (Rehm et al. 2000). The fre-
quency of allergic reactions with albumin is below 0.1% (Laxenaire et 
al. 1994). 
 
3. Crystalloids 
     Crystalloid solutions still remain in wide use as resuscitation fluids. 
This is the oldest group of fluids used for plasma volume replacement. 
Many clinicians use crystalloids because of their safety and low cost. 
Crystalloids, per se, have no effect on renal function or blood coagula-
tion (Ruttmann et al. 2002). The number of different ions in Ringer’s 
acetate solution is nearer that of human plasma than is either unba-
lanced HES or gelatin. Ringer’s solution has therefore been used in 
the ICUs postoperatively.   
     Some investigators have shown that crystalloids improve hemody-
namics and tissue perfusion as well as do albumin or HES solutions 
(Lang et al. 2001, Klein et al. 2002, Finfer et al. 2004). The large me-
ta-analysis could demonstrate no benefit in critically ill patients’ out-
come with the use of either crystalloid or colloid solutions (Perel and 
Roberts 2007). Several clinical studies have demonstrated a higher 
amount of extravascular lung water during use of crystalloids, which 
can aggravate tissue edema and worsen lung function (Lang et al. 
2001, Vrancken et al. 2005).       
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     Ringer’s solution is successful for priming of the CPB circuit. A 
study by Tølløfsrud and co-workers (1995) showed that Ringer’s solu-
tion can raise the amount of extravascular lung water and of tissue 
edema intraoperatively.  
 
4. Thromboelastometry  
 
4.1 Original thromboelastometry 
     Thromboelastography was first described in 1948 by Hartert, but 
this method was not used for the detection of coagulation disturbances 
clinically until 1980 (Luddington 2005). The TEM method was devel-
oped from thromboelastography, and few technical differences be-
tween them exist. Clinical use of TEM started after 2000. This method 
provides a graphic interpretation of viscoelastic changes in whole 
blood and evaluates the process of clot initiation, formation, and sta-
bility as well as lysis. TEM has the capability to give bedside summa-
rized (within 30 minutes) information on platelet function, coagulation 
factors and inhibitors, and fibrinolysis. The use of native whole blood 
is not practical in the laboratory or operation theatre, as the unanticoa-
gulated sample must be analyzed within a few minutes. Therefore, the 
TEM instrument uses citrated blood samples (Zambruni et al. 2004). 
The use of citrated blood in the time range of 0.5 to 4 hours after sam-
pling has been recommended. 
     For TEM, blood is incubated at 37 °C in a heated cup. A pin con-
nected to an optical detector system is suspended in the cup. The pin is 
oscillated at an angle of 4°45' relative to the cup, the motion being in-
itiated by the pin. As fibrin forms between the cup and pin, the change 
in impedance of rotation of the pin is detected by a light beam; a TEM 
trace is generated (Luddington 2005). A normal TEM tracing is pre-
sented in Figure 2. 
The parameters of TEM (Fig. 2) are:  
1. Clotting time (CT) – the time before the beginning of blood coagu-
lation which depends upon fibrin meshing.  
2. Clot formation time (CFT), a measure of the velocity of fibrin 
meshing. CT and CFT are prolonged by warfarin and by deficits in 
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coagulation factors, and are shortened in hypercoagulation situations 
such as hyperfibrinogenemia. 
3. Maximum clot firmness (MCF) measures the strength of the devel-
oped clot and depends upon platelet function, coagulation factors, and 
especially fibrinogen concentration. Several studies have shown that 
MCF correlates with amount of bleeding. 
4. An α-angle also reflects clot development. 
5. Shear elastic modulus (G) is a parametric measure of clot strength 
expressed in metric units calculated from MCF (Niemi et al. 2006): G 
= 5000 x MCF
 
[100 – MCF] – 1.  
6. Lysis 30 and 60 (LY30 and LY60) measure the percentage of lysis 
at 30 minutes and 60 minutes after achievement of MCF. 
 Figure 2. Normal thromboelastometry tracing and parameters (re-
printed with permission from TEM Innovations GmbH, Munich, 
Germany).     
 
 
4.2 Modified thromboelastometry 
    Different possibilities exist to modify TEM. Coagulation can be ex-
amined in the presence of different reagents in order to detect changes 
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at the different levels of the coagulation cascade (Ganter and Hofer 
2008).  
     The InTEM reagent contains contact activator (partial thrombop-
lastin phospholipid) and can detect changes in clot formation and fi-
brin polymerization via the intrinsic pathway (preceded by coagula-
tion factors VIII-XII). 
     The ExTEM reagent contains tissue factor (thromboplastin) and 
has the power to assess parameters via the extrinsic pathway (pre-
ceded by coagulation factors VII, X).  
     To the FibTEM reagent, cytochalasin D is added, which removes 
the role of platelet function. Therefore, FibTEM shows only the fibrin 
contribution to clot formation. It is also possible to evaluate the impact 
of platelets on clotting by calculating the MCF difference between 
ExTEM and FibTEM. 
     To the ApTEM reagent, aprotinin is added to inhibit fibrinolysis. 
The degree of fibrinolysis is determined by evaluating the difference 
in TEM parameters between ExTEM and ApTEM. 
     HepTEM contains heparinase, and EcaTEM ecarin. Use of Hep-
TEM allows detection of clot formation in spite of the presence of he-
parin. EcaTEM has been useful with direct thrombin inhibitors.  
     The modern TEM instrument has four channels to allow the possi-
bility to use simultaneously four different reagents. 
 
4.3 Clinical implications  
     TEM has served successfully as a point-of-care coagulation moni-
tor and has been able to describe bedside changes in the coagulation 
system thoroughly within only 30 minutes. The best impact of TEM 
has been demonstrated in cardiac surgery, in trauma, in obstetric, and 
in hepatic-failure patients (Rugeri et al. 2007, Tripodi et al. 2009).  
     Several studies have shown that after cardiac surgery, inclusion of 
TEM in the treatment algorithm reduces blood product transfusion 
need  (Spiess et al. 1995) as well as bleeding and reoperation rates 
(Welsby et al. 2006, Rahe-Meyer et al. 2009). Anderson and co-
workers (2006) reported that inclusion of TEM in the transfusion algo-
rithm after cardiac surgery can reduce red blood cell transfusion from 
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60% to 53%, FFP transfusion from 17% to 12%, and platelets transfu-
sion from 16% to 11%. 
     A recent study also demonstrated a strong correlation between 
MCF and CFT with postoperative bleeding after cardiac surgery by 
use of different TEM reagents (Reinhöfer et al. 2008). TEM during 
cardiac surgery in cases of bleeding provides the possibility of early 
diagnosis and treatment of coagulation disturbances; a TEM-guided 
algorithm for the use of blood products is applied in some cardiac sur-
gical centers. 
     Using InTEM, ExTEM, FibTEM and ApTEM reagents (Straub et 
al. 2008, Rahe-Meyer et al. 2009), it is possible to detect and treat, 
early, various coagulation disturbances. The Rahe-Mayer group dem-
onstrated a reduction in allogenic blood product transfusion after CPB 
in patients undergoing thoracoabdominal aorta surgery. Those patients 
with excessive bleeding received fibrinogen to attain a target MCF by 
use of FibTEM reagent before standard therapy with platelets and 
FFP. A few case reports concern the use of ApTEM reagent in the 
evaluation and treatment of fibrinolysis in major surgery (Vorweg et 
al. 2001).   
 
5. Cardiopulmonary bypass 
 
5.1 Risk for bleeding after cardiopulmonary bypass 
     CPB predisposes patients to major hemorrhagic complications, and 
possibly to early bypass-related thrombotic events, as well (Parolari et 
al. 2003, Hekmat et al. 2004). The incidence of excessive postopera-
tive bleeding in cardiac surgery exceeds 10%, and approximately 5 to 
7% of patients experience blood loss in excess of 2 L within the initial 
24 hours postoperatively (Despotis et al. 2001).  
     Among patients undergoing isolated CABG, surgical reexploration 
for postoperative bleeding is reported in approximately 4%. The spe-
cific site of bleeding, however, is identified in less than 50% of pa-
tients (Dacey et al. 1998, Nuttall et al. 2003). An acquired hemostatic 
defect is often responsible for diffuse mediastinal hemorrhage.  
 
REVIEW OF THE LITERATURE 
 
 
29 
 
 
5.2 Mechanisms of activation of coagulation during cardi-
opulmonary bypass 
     CPB disturbs blood coagulation by several mechanisms (Yavari 
and Becker 2009). Coagulation factors are activated following direct 
contact between circulating blood and the inner surfaces of the extra-
corporeal circuit. During CPB, blood is pumped continuously across 2 
to 2.5 m
2
 of non-biological surfaces (Hyde et al. 1998), and the oxy-
genator, venous reservoir, and arterial line filter represent large blood-
contact areas (Hyde et al. 1998). During CPB, blood is driven under a 
propulsive force through conduits of differing internal diameters. 
Moreover, the patients’ blood mixes with priming and cardioplegia so-
lutions. 
     During CPB, both contact factor and tissue factor activation occur. 
The contact or intrinsic pathway is triggered when factor XII, prekal-
likrein, and high-MW kininogen interface with nonbiological surfaces. 
The tissue factor or extrinsic pathway is triggered when factor VIIa 
complexes with tissue factor being expressed on monocytes, macro-
phages, fibroblasts, platelets, exposed atherosclerotic plaques, or ex-
posed subendothelial constituents within the vessel wall (Boisclair et 
al. 1993). CPB therefore creates prothrombotic and proinflammatory 
conditions.  
     The contact- and tissue factor-activated coagulation pathways 
represent an integrated system designed to generate thrombin. Factor 
Xa with factor Va, calcium, and phospholipid substrate form the 
prothrombinase complex on activated platelets, cleaving prothrombin 
to form thrombin (Edmunds and Colman 2006), which activates plate-
lets and coagulation factors V, VIII, and XI (Moor et al. 1994). 
        
5.2.1 Cardiopulmonary bypass and effects of heparinization on plate-
lets  
 
     Heparin inhibits platelet function (John et al. 1993, Kestin et al. 
1993), reduces platelet count, and influences platelet microaggrega-
tion (Muriithi et al. 2000b). During CPB, platelets that have aggre-
gated are lost from the circulating platelet pool. Previous investigators 
have also reported a preferential loss during extracorporeal circulation 
of activated platelets (Wahba et al. 1996). Activated platelets may 
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contribute to the cytokine production observed during CPB by causing 
endothelial cells to secrete cytokines and adhesion molecules (Henn et 
al. 1998). Platelets sequestered in the body during extracorporeal cir-
culation later return to the circulation and have a normal life span. In 
theory, the inhibitory effect of heparin on platelet aggregation (Belch-
er et al. 2000, Muriithi et al. 2000a) may preserve platelets.  
 
5.2.2 Fibrinolysis during cardiopulmonary bypass 
 
    Fibrinolytic activity increases significantly during and following 
CPB because of intraoperative contact activation, release of tissue 
plasminogen activator due to kallikrein production, use of relatively 
high-dose heparin, and inhibition of α2-antiplasmin (Kongsgaard et al. 
1989, Ray et al. 1994, Altman et al. 1998). Antiplasmin levels do not 
return to normal for 48 to 72 hours postoperatively, whereas plasmin 
levels after discontinuation of CPB return to normal immediately 
(Kongsgaard et al. 1989). Therefore, after CPB, the fibrinolysis acti-
vation is prolonged, which can lead to increased postoperative bleed-
ing (Gelb et al. 1996, Casati et al. 2001, Linden 2003).      
AIMS OF THE PRESENT STUDY 
 
 
31 
 
AIMS OF THE PRESENT STUDY 
 
     The main objective of the present thesis was to determine the ef-
fects of various colloid solutions (6% HES 130/0.4, 6% HES 200/0.5, 
and 4% gelatin) on whole blood coagulation and hemodynamics after 
elective cardiac surgery in patients with preserved cardiac function.  
       The specific goals were to determine: 
1. The effects of a single dose of 15 mL kg-1 of HES 130/0.4 and 
HES 200/0.5 solution (Study I) or repeated doses (between 7 mL kg
-1 
and 28 mL kg
-1
) of the HES 130/0.4 and gelatin solution (Study II) on 
whole blood coagulation after cardiac surgery, as assessed by TEM.  
2. The mechanisms of colloid-induced coagulopathy by TEM analy-
sis in vivo (Studies I, II), and in vitro, using gelatin hemodilution of 
whole blood (Study III). 
3. The hemodynamic profile after a single dose of 15 mL kg-1 of 
HES 130/0.4 and HES 200/0.5 solution (Study IV) or repeated doses 
(between 7 mL kg
-1 
and 28 mL kg
-1
) of HES 130/0.4 and gelatin solu-
tion (Study V) after cardiac surgery by use of a thermodilution me-
thod.  
4. The acid-base equilibrium after administration of HES 130/0.4 
and gelatin (Studies IV, V). 
     A colloid solution of biological origin (4% albumin) or crystalloid 
solution (Ringer’s acetate) served as controls. 
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Study design (I – V) 
     Four prospective clinical studies (I, II, IV, V) were performed, and 
one randomized cross-over in vitro study (III). In each clinical study, 
45 patients scheduled for elective primary cardiac surgery were ran-
domized; 12 apparently healthy volunteers without any medication 7 
days prior to the experiment were included in the in vitro study. The 
Ethics Committee for Surgery in the Hospital District of Helsinki and 
Uusimaa (Studies I – V) and the National Agency of Medicines in 
Finland (I, II, IV, V) approved the study protocols. All patients and 
volunteers gave then written informed consent to participate in each 
study. Study IV included the same patient population as did Study I.  
Study V included the same patient population as did Study II (Table 
1). 
     Patients included showed no renal or hepatic failure. In the clinical 
studies, preoperative cardiac medications were administered on the 
morning of surgery, except for angiotensin-converting enzyme inhibi-
tors and angiotensin II antagonists. Preoperatively, all the patients had 
a normal left ventricular ejection fraction (> 50%). No antithrombotic 
medication was allowed within 5 days prior to surgery. Study charac-
teristics are summarized in Table 1. 
     All the patients received different colloids or Ringer’s acetate solu-
tions in the early postoperative period (0-18 hours after surgery). 
TEM, hemodynamic changes, and the amount of bleeding, blood 
product use, and acid-base equilibrium were studied. 
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Table 1. Study characteristics. 
 Study Subjects n Design Intervention Primary end-point 
I 
Cardiac 
surgery 
patients 
45 
Prospective, ran-
domized, single-
blinded, controlled 
15 mL kg
–1
 of     
6% HES 130/0.4, 
6% HES 200/0.5, 
or 4% albumin 
TEM parameters 
(MCF) 
II 
Cardiac 
surgery 
patients 
45 
Prospective, ran-
domized, single-
blinded, controlled 
7, 14, 21, and     
28 mL kg
–1
 of        
6% HES 130/0.4, 
4% gelatin, or 
Ringer’s acetate 
TEM parameters 
dose-dependently 
(MCF) 
III 
Healthy 
volunteers 
12 
Experimental in 
vitro, randomized, 
cross-over 
40 vol%        
hemodilution 
with 4% gelatin 
TEM parameters 
(MCF) with addi-
tion of coagulation 
factors 
IV 
Cardiac 
surgery 
patients 
45 (same as 
in Study I) 
Prospective, ran-
domized, open, 
controlled 
15 mL kg
–1
 of     
6% HES 130/0.4, 
6% HES 200/0.5, 
or 4% albumin 
Hemodynamics 
(CI, SVI)            
and acid-base equi-
librium 
V 
Cardiac 
surgery 
patients 
45 (same as 
in Study II) 
Prospective, ran-
domized, open, 
controlled 
7, 14, 21, and     
28 mL kg
–1
 of        
6% HES 130/0.4, 
4% gelatin, or 
Ringer’s acetate 
Hemodynamics 
dose-dependently 
(CI, SVI)            
and acid-base equi-
librium 
 
CI = cardiac index, HES = hydroxyethyl starch, MCF = maximum clot 
firmness, SVI = stroke volume index, TEM = thromboelastometry 
 
Clinical study protocols (I, II, IV, V) 
     We recruited 115 patients for the four studies, and 25 were ex-
cluded (Figure 3).  
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Figure 3. Flow chart of patients undergoing elective cardiac surgery. 
 
 
Anesthesia 
     Patients were premedicated with lorazepam 0.03 mg kg
-1 
orally, 
and received fentanyl 5 µg kg
-1
 or sufentanil 2 µg kg
-1 
and propofol    
Assessed for     
eligibility  
(n = 115)    
Excluded (25) 
→ Not meeting inclusion  
      criteria (3) 
→  Declined to participate (2) 
→  Change of operation type (6) 
→  Perioperative excessive bleeding (4) 
→  Other complications (6) 
→  Other reasons (4) 
 
 
 Randomized and allocated to 
 intervention (90) 
 
Receiving 
HES 130/0.4 
(30) 
Receiving 
gelatin  
(15) 
 
Receiving 
HES 200/0.5  
(15) 
 
Receiving 
albumin 
(15) 
 
Receiving 
Ringer’s 
acetate 
(15) 
 
Analyzed  
(30) 
Analyzed  
(15) 
Analyzed  
(15) 
 
Analyzed  
(15) 
 
Analyzed  
(15) 
 
Protocol devia-
tion: no thermo-
dilution catheter 
(2) 
Protocol devia-
tion: no ther-
modilution 
catheter 
(1) 
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1 to 1.5 mg kg
-1
 or
 
etomidate 0.2 mg kg
-1
 for induction of anesthesia. 
Rocuronium served as the neuromuscular blocking drug.
 
Anesthesia 
was maintained with a continuous infusion of fentanyl 5 µg kg
-1
 h
-1
 or 
sufentanil 1.5 to 2 µg kg
-1
 h
-1
 until the end of surgery. Sevoflurane 
supplementation (inspiratory concentration 2.5 to 3%) was used to 
achieve a bispectral index level
 
below 50. After surgery, patients were 
transported to the cardiac surgical ICU under propofol sedation and on 
mechanical ventilation.  
 
Cardiopulmonary bypass  
     CPB was instituted with a nonpulsatile pump and a membrane 
oxygenator. The bypass circuit was primed with 2000 mL of Ringer’s  
acetate solution and 100 mL of 15% mannitol. During cardiac arrest, 
the patients were kept in mild hypothermia (nasopharyngeal tempera-
ture between 30 and 33°C). For CPB, the patients were anticoagulated 
with
 
heparin 300 IU kg
-1
, and 5000 IU of heparin was added to the 
priming
 
solution. Activated clotting time (ACT using kaolin activator) 
was measured every
 
30 minutes and kept above 480 s during CPB 
with additional doses
 
of 5000 IU of heparin if required. During CPB, 
hematocrit was kept above 20%. After CPB, heparin was neutralized 
with 1 mg of protamine for each 100
 
IU of the initial dose of heparin. 
Additional doses of 25 mg
 
of protamine were given to achieve the pre-
bypass ACT level.
 
Shed mediastinal blood was not retransfused. After 
termination of CPB, blood from the CPB circuit was collected into
 
nonanticoagulated blood bags and retransfused. During CPB all the 
patients were rewarmed (nasopharyngeal temperature up to 36°). 
Intraoperatively, only Ringer’s acetate solution was administered. 
 
Surgery 
     Several types of elective primary cardiac surgery using CPB were 
included: coronary artery bypass grafting (CABG), valve replacement 
or valve repair, or combined coronary and valve surgery. The cardiac 
surgery was not standardized, but all patients underwent full median 
sternotomy.   
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Study fluids 
     After admission to the cardiac surgical ICU, patients were rando-
mized to receive one of the study solutions. The randomization was 
performed by means of closed
 
envelopes prepared before the begin-
ning of the study by a person not participating in the study. Thereafter, 
the predetermined dose of study solution was administered at the rate 
necessary to achieve or maintain pulmonary capillary wedge pressure 
(PCWP) between 10 and 15 mmHg. The dosing regimen of the study 
solutions was the following:  
     Studies I, IV: a single dose of 15 mL kg
-1 
of 6% HES 130/0.4, 6% 
HES 200/0.5, or 4% albumin solutions. 
     Studies II, V: four repeated doses of 7 mL kg
-1
 (resulting in cumu-
lative doses of 7 mL kg
-1
, 14 mL kg
-1
, 21 mL kg
-1
, and 28 mL kg
-1
) of 
6% HES 130/0.4, 4% gelatin, or Ringer’s acetate solutions (Table 2). 
     Study III was carried out in vitro: venous blood collected from vo-
lunteers was diluted by 4% gelatin solution to make 40 vol%. hemodi-
lution.  
Table 2. Characteristics of the study solutions. 
 
6% HES 
130/0.4 
4% GEL 
6% HES 
200/0.5 
4% ALB RIN 
Study  I, II, IV, V II, III, V I, IV I, IV II, V 
Average MW, kDa 130 30 200 65 - 
pH 4.0-5.5 7.1-7.7 3.5-6 7 6.0 
Sodium, mmol L
–1
 154 154 154 154 131 
Chloride, mmol L
–1
 154 120 154 154 112 
Acetate, mmol L
–1
 - - - - 30 
Osmolality, mOsm L
–1
 308 274 308 NA 270 
 
ALB = 4% albumin, GEL = 4% gelatin, HES = hydroxyethyl starch, 
MW = molecular weight, NA = not available, RIN = Ringer’s acetate 
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Hemodynamic management and fluid therapy postopera-
tively 
     After surgery, PCWP was maintained between 10 and 15 mmHg, 
and CI over 2.0 L min
–1
 m
–2
. After administration of the fixed dose of 
study solution, Ringer’s acetate was administered in cases of hypovo-
lemia (PCWP < 10 mmHg). An epinephrine infusion was initiated 
(0.02 to 0.1 µg kg
-1 
min
-1
) when the CI remained < 2.0 L kg
-1 
min
-1
 de-
spite a PCWP between 10 and 15 mmHg. A norepinephrine infusion 
(0.03 to 0.3 µg kg
-1 
min
-1
) was started whenever the mean systemic ar-
terial blood pressure fell below 70 mmHg despite the targeted PCWP 
and CI. 
 
Red blood cells, fresh frozen plasma, and platelet concen-
trate transfusion triggers 
     In clinical studies (I, II, IV, V), red blood cells (RBC) were trans-
fused after CPB if hemoglobin (Hb) concentration fell under 80 g L
-1
. 
During CPB, hematocrit was kept between 20 to 25%. In the cardiac 
surgical ICU, ACT, prothrombin time value, and platelet count were 
determined if postoperative blood loss exceeded 200 mL h
–1
. If ACT 
was prolonged more than 10 s compared with its pre-bypass level, 25 
mg of protamine was administered. If prothrombin time was greater 
than 30 s, 10 mL kg
-1 
of FFP was transfused. If platelet count fell be-
low 50 · 10
9
 L
–1
, 1 unit 10 kg
–1
 platelet concentrate was administered. 
If the bleeding continued, 1g of tranexamic acid was given. 
 
In vitro study protocol (III) 
     A venous blood sample was obtained twice from a dozen apparent-
ly healthy volunteers, six male and six female. An undiluted citrated 
blood sample served as a control. The 40 vol%. hemodilution per-
formed corresponds to the rapid administration of 2000 mL of gelatin 
solution to any patient with acute bleeding.  
     Various coagulation factors were added to the diluted blood sam-
ples at room temperature in random order 5 to 10 min prior to analy-
sis:  
1. FVIII+vWF, 80 µL mL
-1 
(Haemate P®, CSL, Behring, Marburg, 
Germany) (FVIII+vWF), 
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2. FXIII, 100 µL mL
-1 
(Fibrogammin®, CSL, Behring) (FXIII), 
3. Fibrinogen, 60 µL mL
-1 
(Haemocomplettan P®, CSL, Behring) (Fi-
brinogen), or  
4. FFP, 210 µL mL
-1 
(Finnish Red Cross Transfusion Service, Helsin-
ki, Finland).  
     Hb concentration, hematocrit, and platelet count were analyzed in 
all blood samples. To define the impact of fibrinogen and platelets on 
the changes in blood coagulation, modified TEM was performed with 
ExTEM
 
and FibTEM reagents. 
     Transferring this in vitro model to in vivo conditions, the doses of 
various coagulation factors in cuvettes corresponded to a single dose 
of 1000 IU of Haemate P, 1250 IU of Fibrogammin, 3 g of Haemo-
complettan P, or 15 mL kg
-1 
of FFP administered to an adult patient of 
approximately 70 kg of body weight and a blood volume of 5 liters. 
These doses are recommended for the treatment of moderate or severe 
bleeding. 
 
Outcome measurements 
 
Major outcome measurements 
     The major outcomes were maximum clot firmness measured by 
TEM analysis (ROTEM®;
 
TEM Innovations GmbH, Munich, Germa-
ny) (Studies I, II, III) and cardiac and stroke volume index (Studies 
IV, V) measured by the thermodilution method using a pulmonary ar-
tery catheter. 
     A decreasing MCF is a major risk factor for bleeding after cardiac 
surgery (Rahe-Meyer et al. 2009). Specific reagents in TEM will 
make it possible to detect the impact of fibrin and platelets on coagu-
lation (Rienhöfer et al. 2008). The pulmonary artery catheter is widely 
accepted in cardiac surgery for the monitoring of hemodynamics. By 
means of this catheter, it is possible to determine the CO, CI, and SVI 
as well as pre- (central venous pressure (CVP), PCWP) and postload 
(pulmonary vascular resistance index [PVRI], systemic vascular resis-
tance index [SVRI]).  
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Thromboelastometry measurements (I, II, III) 
     The modified TEM was performed using four commercial reagents 
which were intrinsic
 
ROTEM (InTEM®), extrinsic ROTEM (Ex-
TEM®),
 
fibrinogen ROTEM (FibTEM®), aprotinin ROTEM (Ap-
TEM®). FibTEM was used to evaluate the impact of fibrinogen on 
blood coagulation, and ApTEM to detect possible activation of fibri-
nolysis. The ROTEM instrument was calibrated according to manu-
facturer’s instructions.  
    
 
Coagulation was initiated with activators by means of a semiauto-
matic
 electronic pipette according to manufacturer’s instructions. Coa-
gulation was allowed to proceed for 60 minutes in clinical studies, and 
for 30 minutes in Study III. Automatic
 
ROTEM variables were clot-
ting time (CT, s), clot formation time (CFT, s), α-angle (α, degree), 
maximum clot firmness
 
(MCF, mm), and clot lysis after 30 and 60 
minutes (LY30 and LY60). The effect of platelets
 
on clot strength was 
assessed as follows: Platelet MCF = ExTEM MCF – FibTEM MCF 
(Lang et al. 2009).  
     In clinical studies, TEM was performed after surgery, after each 
dose of study solutions (Studies I, II), and on the first postoperative 
morning (Study II only). TEM analysis before intervention (after sur-
gery) served as the control for each patient. 
 
Hemodynamic measurements (IV, V) 
     Before anesthesia, the left or right radial artery was catheterized for 
measurement of systemic blood pressure. After induction and intuba-
tion, the pulmonary artery catheter (Swan-Ganz catheter®, Edwards 
Lifesciences, Unterschleisheim, Germany GmbH) was placed via an 
internal jugular vein. Hemodynamic measurements included heart rate 
(HR), mean arterial blood pressure (MAP), pulmonary artery pressure 
(PAP), CVP, PCWP, and CO. CO was measured by triplicate thermo-
dilution using ice-water; CI, SVRI, PVRI, and SVI were calculated 
from these measurements. 
     Hemodynamic measurements were performed after surgery, after 
each dose of study solutions, and on the first postoperative morning 
(Studies IV, V). 
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Blood sampling and laboratory analyses 
 
Blood sampling 
     In clinical studies, arterial blood samples were collected before the 
start of fluid infusion (when the patient reached the ICU), after each 
dose of the study solution, and on the first postoperative morning via a 
nonheparinized
 
radial artery catheter. Blood samples for TEM were 
collected into polypropylene tubes containing 3.2% buffered
 
citrate, 
which stabilized the sample for a period of 4 hours. This method was 
determined to be safe without significant changes in TEM in compari-
son with unstable native blood, and the ROTEM instrument is cali-
brated for citrate-coagulated blood samples (Zambruni et al. 2004). 
 
Laboratory analyses 
     Hb concentration, hematocrit, and platelet count in arterial blood 
samples were analyzed by the Cell-Dyn 610 hematology
 
analyzer (Se-
quila-Turner Corp., Mountain View, CA). Partial pressure of oxygen 
(PaO2) and of carbon dioxide in arterial blood (PaCO2), pH, lactate, 
chloride, and ionized calcium were measured, and the standard serum 
bicarbonate concentration and base excess (BE) were calculated with 
an ABL 825 blood gas analyzer (Radiometer Medical A/S, Copenha-
gen, Denmark) using the Henderson-Hasselbalch equation and the 
Siggaard-Andersen nomogram (Siggaard-Andersen 1963). In addition, 
the SvO2 was measured, and oxygen delivery (DO2 = 10 x (0.136 x Hb 
/ 100 + 0.0031 x PaO2) x CO), consumption (VO2 = CO x avD02), and 
strong ion difference (SID = [Na
+
] + [K
+
] - [lactate
-
] - [Cl
-
]) (Stewart 
1983) were calculated before and after the each dose of the study solu-
tion, and on the first postoperative morning.  
 
Statistical analyses  
     Number of study subjects was based on observations of MCF in a 
previous study (Niemi et al. 2006). A difference of 15% in MCF was 
considered significant. Thus, the number of subjects needed was 13 by 
group in comparison of two groups with an α-error of 0.05 and ß-error 
of 0.2. It also was estimated that 12.8 patients were needed in each 
group to detect a 20% difference in CI (standard deviation (SD) 0.5 L 
PATIENTS AND METHODS 
41
min-1 m-2) after the end of infusion of the study solution. Data distri-
bution was tested by the Kolmogorov-Smirnov test. Analysis of va-
riance (ANOVA) or the Kruskal-Wallis test was applied to detect any 
difference between or within groups. For multiple comparisons, Bon-
ferroni correction was used. A paired t-test, Student-Newman-Keuls 
test, or Wilcoxon test served for paired comparisons. The results are 
reported as means with SD, or medians with quartiles (25th to 75th per-
centiles), if data were not normally distributed. The results of CI and 
SVI are also shown as means with 95% confidence intervals (Study 
V). The frequencies were tested by 2 test. A p value < 0.05 was con-
sidered statistically significant. All the statistical measurements were 
performed by SPSS for Windows (version 15.0). 
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RESULTS 
 
     All patients and volunteers who were initially included completed 
the study. In Study III all the hemodilutions were successful. In Study 
V, measurement of CI was impossible in three patients due to techni-
cal reasons. All TEM measurements were successful. The results of 
TEM of healthy volunteers (Table 3) are comparable with those of 
other studies, which indicates the reliability of the present observa-
tions.  
     Table 3. TEM variables in healthy volunteers (Study III, undiluted 
sample) (reprinted with permission from Wiley-Blackwell). 
 Mean±SD Range 
CT      ExTEM 
(s)        FibTEM 
68.8±13.4 
61.8±14.8 
52-95 
41-84 
CFT    ExTEM 
(s)        FibTEM 
109.7±44.7 
NA 
61-201 
NA 
MCF   ExTEM 
(mm)    FibTEM 
58.6±9.1 
14.8±4.7 
44-72 
11-22 
α        ExTEM 
(º)        FibTEM 
69.0±7.1 
65.2±8.8 
55-78 
53-78 
LY30      ExTEM 
(100-%)  FibTEM 
98.9±2.3 
99.6±0.7 
93-100 
98-100 
G        ExTEM 
(U)      FibTEM 
7507±2702 
890±3432 
3872-12674 
596-1451 
 
CFT = clot formation time, CT = clotting time, G = shear elastic 
modulus, LY30 = clot lysis after 30 minutes, MCF = maximum clot 
firmness, mm = millimeter, NA = not available, s = second, SD = 
standard deviation, U = unit, α = α-angle, º = degree 
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Effects of colloids on whole blood coagulation (I, 
II) 
     In the early postoperative period after cardiac surgery, HES 
130/0.4, HES 200/0.5, and gelatin solutions impaired whole blood 
coagulation as measured by TEM. After a dose of 15 mL kg
–1 
of both 
HES solutions, MCF decreased and CFT increased compared to val-
ues for human albumin (in Study I, Figure 1). At 2 h, after all of the 
study solution was infused, the coagulation disturbances partially re-
covered (using InTEM and ExTEM reagents). In Study II, MCF de-
creased and CFT increased even after a small dose (7 mL kg
–1
) of col-
loid solutions compared to the effect of Ringer’s acetate, and these 
TEM changes became more pronounced with the larger doses of HES 
and gelatin solutions used, in a dose-dependent manner (Table 4). On 
the first postoperative morning, all TEM parameters were comparable 
among all groups (Study II). 
     Albumin caused no coagulation disturbances. The use of Ringer’s 
acetate at a dose of 14 mL kg
–1
 raised MCF slightly but significantly 
above its pre-infusion level (Study II). 
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Table 4. Study II. Initial fibrin formation and build-up (ROTEM) be-
fore (Pre), and after each bolus of the study infusion (7mL kg
–1
, 14 
mL kg
–1
, and 21 mL kg
–1
), and on the first postoperative morning      
(1 POM) using ExTEM reagent (reprinted with permission from Ox-
ford Journals).  
 
 HES 130/0.4 4% gelatin   Ringer’s acetate 
ExTEM MCF (mm) 
Pre 
7mL kg
–1
 
14 mL kg
–1 
21 mL  kg
–1
 
1 POM (28 mL  kg
–1
) 
 
57.9 (5.6) 
55.1 (5.6)† 
51.7 (5.9)† 
51.1 (6.2)† 
59.9 (5.2) 
 
56.9 (4.2) 
54.9 (4.4)† 
53.6 (3.6)† 
52.3 (3.9)† 
56.6 (4.4) 
 
58.5 (5.0) 
59.7 (3.9)* 
60.4 (4.7)*† 
61.4 (3.4)* 
61.7 (3.4)# 
ExTEM CFT (s) 
Pre 
7mL kg
–1
 
14 mL kg
–1 
21 mL  kg
–1
 
1 POM (28 mL  kg
–1
) 
 
110.8 (39.8) 
141.3 (45.0)† 
169.5 (57.7)† 
200.1 (89.0)† 
124.6 (46.4) 
 
121.2 (32.4) 
136.8 (40.2 ) 
145.9 (39.7)† 
163.9 (36.8)† 
135.7 (34.1) 
 
104.7 (19.2) 
101.1 (22.1)* 
96.0 (18.0)* 
97.3 (14.2)* 
102.1 (18.9)# 
 
Values are means (SD). CFT = clot formation time, HES = hydroxye-
thyl starch, MCF = maximum clot firmness. 
One-way ANOVA, and T-test. *p < 0.05 Ringer’s acetate  vs. HES 
and gelatin, #p < 0.05 RIN vs. gelatin, p < 0.05 gelatin vs. HES and 
Ringer’s acetate, +p < 0.05 Ringer’s acetate vs. HES (Bonferroni post 
hoc test), †p < 0.05 between pre and 7 mL kg–1, 14 mL kg–1 , 21 mL 
kg
–1
 and 1 POM (T-test) 
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Mechanism of coagulation disturbance after use of 
colloids (I-III) 
     No differences appeared in MCF or CFT between ExTEM and Ap-
TEM reagents, nor any changes in platelet MCF (ExTEM MCF - Fib-
TEM MCF) after administration of any of the study solutions (Studies 
I, II). 
     All the clot lysis parameters before and after use of these solutions 
fell within the normal range in the postoperative period (Studies I, II).  
       In Study III, the 40 vol% dilution with gelatin reduced MCF and 
raised CFT. FFP caused a partial correction of ExTEM values. The ef-
fect on TEM of fibrinogen, FVIII+vWF, or FXIII was minimal.  
     In the FibTEM tracing, all the coagulation factors improved MCF, 
but the MCF was significantly higher after administration of fibrino-
gen or FFP than after FVIII+vWF and FXIII (Table 5). 
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Table 5. Results of MCF and CFT (Study III) (reprinted with permis-
sion from Wiley-Blackwell). 
 
MCF 
(% of undiluted value) 
CFT 
(% of  undiluted value) 
ExTEM                               
Undiluted control 
100.0 100.0 
+Gelatin 40% 76.3 (65.9-80.0)# *+ 270.3 (229.2-404.9)# 
+Fibrinogen 74.0 (62.8-76.5)#*+ 312.7 (279.1-363.8)#* 
+FVIII+vWF 67.2 (50.6-73.8)#* 320.9 (268.1-467.7)#* 
+FXIII 68.1 (58.3-72.9) #* 303.7 (271.4-396.2)#* 
+ FFP 80.8 (76.4-83.5)# 226.7 (214.4-253.3)# 
FibTEM                              
Undiluted control 
100.0 NA 
+Gelatin 40% 32.5 (27.4-45)# *†+ NA 
+Fibrinogen 66.9 (53.0-81.8)#* NA 
+FVIII+vWF 48.5 (37.4-53.7)#*† NA 
+FXIII 46.7 (38.1-69.6)#† NA 
+ FFP 57.1 (47.8-73.1)# NA 
 
Medians (25
th
 to 75
th
 percentiles) are shown. CFT = clot formation 
time, FFP = fresh frozen plasma, FVIII+vWF = coagulation factor 
VIII+von Willebrand factor, FXIII = coagulation factor XIII, MCF = 
maximum clot firmness, NA = not available. 
Student-Newman-Keuls test. *p < 0.05 compared with FFP, †p < 0.05 
compared with fibrinogen, +p < 0.05 compared with FVIII+vWF and 
FXIII, #p < 0.001 compared with undiluted sample  
      
     In Studies I and II, Hb concentration, hematocrit, and platelet count 
were decreased after infusion of HES 130/0.4, HES 200/0.5, and gela-
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tin solution, but remained unchanged in the Ringer’s and albumin 
groups. On the first postoperative morning, all these parameters were 
comparable between the groups, except that Hb concentration in the 
albumin group was significantly lower (p = 0.046) than in the HES 
200/0.5 group (Study I). 
 
Effects of colloids and crystalloids on hemody-
namics (IV, V) 
     All colloids raised CI and SVI and maintained hemodynamics suc-
cessfully in the early postoperative period. The effects of 15 mL kg
–1 
of HES 130/0.4 and HES 200/0.5 on CI and SVI were similar and sig-
nificantly higher than those of albumin solution immediately after 
completion of the infusion (in Study IV, Figures 1, 2). In Study V, the 
effect of HES 130/0.4 on CI and SVI was stronger than that of the ge-
latin and Ringer’s acetate solutions at a dose of 7 mL kg–1. At this 
stage, no differences emerged in CI and SVI between the gelatin and 
Ringer’s groups. When the dose of colloid increased (14 mL kg–1 to 21 
mL kg
–1
), the effect of gelatin on CI and SVI was comparable to that 
of HES 130/0.4 solution, and superior to that of Ringer’s acetate. Rin-
ger’s acetate changed neither CI nor SVI. On the first postoperative 
morning, the hemodynamic values in all the groups were similar 
(Tables 6, 7). No low-output syndrome appeared postoperatively, and 
use of vasoactive agents between groups in the studies was similar.  
     CVP and PCWP were held successfully at target level, and MAP 
did not differ between the groups during the entire study period. Only 
after a cumulative dose of 21 mL kg
-1
, PCWP was higher in the HES 
130/0.4 group than in either the gelatin or Ringer’s group (p = 0.03). 
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Table 6. Cardiac index after infusion of 7, 14, 21, or 28 mL kg
-1 
of the 
study fluid (reprinted with permission from SAGE).  
 
HES 
n = 15 
GEL 
n = 14 
RIN 
n = 13 
95% CI 
HES vs. GEL 
95% CI 
HES vs. RIN 
95% CI 
GEL vs. RIN 
Pre                
L min
-1
 m
-2
 
2.1 (0.5) 1.9 (0.5) 
2.0 (0.7)         
p = 0.702# 
-0.18-0.50 -0.40-0.40 -0.60-0.29 
7 mL kg
-1       
 
L min
-1
 m
-2
 
2.8 (0.6)+ 2.4 (0.5)+ 
2.2 (0.4)         
p = 0.031# 
0.00-0.80* 0.11-1.00* -0.20-0.50 
14 mL kg
-1     
L min
-1
 m
-2
 
3.1 (0.8)+ 2.8 (0.6)+ 
2.2 (0.3)         
p = 0.002# 
-0.20-0.80 0.46-1.30* 0.30-1.00* 
21 mL kg
-1     
L min
-1
 m
-2
 
3.4 (1.0)+ 2.9 (0.6)+ 
2.3 (0.53)       
p = 0.004# 
-0.09-1.10 0.50-1.70* 0.20-1.00* 
28 mL kg
-1     
L min
-1
 m
-2
 
3.1 (0.7)+ 2.9 (0.5)+ 
2.8 (0.4)+      
p = 0.507# 
-0.26-0.60 -0.15-0.69 -0,24-0,44 
 
Values are means (SD). CI = confidence interval, GEL = gelatin, HES 
= hydroxyethyl starch, Pre = before infusion of study solution, RIN = 
Ringer’s acetate. 
*p < 0.05, +p < 0.005 in comparison with Pre within group (T-test), 
#ANOVA test served for comparison between groups  
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Table 7. Stroke volume index after infusion of 7, 14, 21, or 28 mL kg
-1 
of the study fluid (reprinted with permission from SAGE).   
 
HES 
n = 15 
GEL 
n = 14 
RIN 
n = 13 
95% CI   
HES vs. GEL 
95% CI   
HES vs. RIN 
95% CI   
GEL vs. RIN 
Pre                 
mL m
-2
 
25.4 (4.8) 22.0 (5.5) 
23.3 (8.6)     
p = 0.377# 
-0.77 - 6.80 -3.10-7.10 -6.30-4.30 
7 mL kg
-1          
mL m
-2
 
34.1 (6.7)+ 28.1 (6.2)+ 
25.8 (7.2)     
p = 0.006# 
1.30-10.70* 2.90-13.10* -2.90-6.90 
14 mL kg
-1       
mL m
-2
 
37.3 (8.1)+ 31.9 (7.2)+ 
25.4 (4.1)     
p = 0.000# 
-0.60-10.60 7.30-16.70* 2.70-11.30* 
21 mL kg
-1       
mL m
-2
 
42.8 (16.2)+ 33.8 (7.3)+ 
26.7 (6.4)     
p = 0.004# 
-0.20-18.20 7.00-25.00* 2.00-12.00* 
28 mL kg
-1       
mL m
-2
 
36.1 (7.1)+ 33.4 (8.0)+ 
34.2 (7.5)+    
p = 0.601# 
-2.50-8.50 -3.30-7.30 -6.70-4.70 
 
Values are means (SD). CI = confidence interval, GEL = gelatin, HES 
= hydroxyethyl starch, Pre = before infusion of study solution, RIN = 
Ringer’s acetate. 
*p < 0.05, +p < 0.005 in comparison with Pre within group (T-test), 
#ANOVA test served for comparison between groups  
 
     SvO2 was higher in the HES 130/0.4 group than in the Ringer’s 
group (Study V), with no difference in DO2 and VO2 between these 
groups. 
     No differences in acid-base equilibrium appeared between any of 
the study solutions. SID was slightly higher after infusion of 14 mL 
kg
–1
 or more of gelatin solution than it was with HES or Ringer’s ace-
tate solutions (Study V). 
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Blood loss and fluid balance 
     Chest tube drainage in all groups was similar. None of the single 
clinical studies detected differences in blood-product use postopera-
tively, but when Studies I and II were analyzed together, the cumula-
tive use of RBC on the first postoperative morning was higher after 
the administration of gelatin (1.47±2.0 U/patient) than with Ringer’s 
acetate or albumin (p < 0.015). The use of RBC, however, was similar 
after HES and gelatin administration. Use of FFP or platelet concen-
trate did not differ between the study groups intra- and postoperative-
ly. The fluid balance, including postoperative crystalloid solutions 
administered and use of vasoactive drugs, was similar in all study 
groups. Urine output was higher in both HES groups (p < 0.035) than 
in the Ringer’s acetate or gelatin group (Table 8).   
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Table 8. Postoperative fluid balance and cumulative number of trans-
fused blood products on the first postoperative morning.     
 
HES 130/0.4 
n = 30 
GEL 
n = 15 
RIN 
n = 15 
HES 200/0.5 
n = 15 
ALB 
n = 15 
p all 
groups 
RBC transfusion 
(U/patient) 
0.77 (1.1) 1.47 (2.0)* 0.23 (1.6) 0.87 (0.64) 0.4 (0.63) 0.047 
FFP transfusion 
(U/patient) 
0.33 (1.5) 0.13 (0.52) 0.29 (1.1) 0.2 (0.78) 0.0 (0.0) 0.881 
PLC transfusion 
(U/patient) 
0.93 (2.5) 1.3 (2.9) 1.1 (4.3) 1.1 (2.8) 0.0 (0.0) 0.717 
Ringer’s acetate            
(mL 18 hours
-1
) 
1628 (1500) 1704 (1077) 1300 (918) 1701 (895) 1620 (820) 0.903 
Chest tube drainage             
(mL 18 hours
-1
) 
923 (329) 1099 (420) 921 (367)  989 (510)  934 (230) 0.62 
Chest tube drainage             
(mL kg
-1 
18 hours
-1
) 
11.4 (5.3) 15.0 (6.7) 12.7 (4.3) 11.7 (5.8)  12.8 (5.2) 0.311 
Urine output         
(mL 18 hours
-1
) 
3732 (1321)† 2923 (1040) 2509 (753) 3919 (1644)† 3143 (782) 0.005 
 
Values are means (SD). ALB = 4% albumin, FFP = fresh frozen plas-
ma, GEL = 4% gelatin, HES = hydroxyethyl starch, PLC = platelet 
concentrate, RBC = red blood cells, RIN = Ringer’s acetate.  
One-way ANOVA, and T-test. *p < 0.015 in comparison with RIN 
and ALB (Bonferroni post hoc test), †p < 0.035 in comparison with 
GEL and RIN (Bonferroni post hoc test) 
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DISCUSSION 
 
Colloids and crystalloids after cardiac surgery: 
coagulation 
     This study showed that the new HES and gelatin solutions have a 
comparable effect on whole blood coagulation as measured by mo-
dified TEM. HES and gelatin slightly reduced clot strength and pro-
longed CFT. These changes in TEM, however, were not reflected in 
postoperative blood loss. Postoperative bleeding on the first postoper-
ative morning was similar in the HES, gelatin, albumin, and Ringer’s 
acetate groups.  
     Earlier studies have demonstrated that the use of HES solutions 
with a higher degree of substitution (0.6-0.7) predisposes patients to 
increased bleeding after cardiac surgery (Wilkes et al. 2001, Kuitunen 
et al. 2004). Therefore, HES solutions with lower MW and a lower 
degree of substitution have been developed (i.e., HES 130/0.4). The 
coagulation disturbances caused by modern HES solutions do not 
seem to be related to increased postoperative bleeding after various 
types of major surgery (Langeron et al. 2001, Kozek-Langenecker et 
al. 2008). The present study demonstrated that the effects of HES and 
gelatin solutions on blood loss are similar. Neither colloid caused in-
creased postoperative chest tube drainage in comparison with Ringer’s 
acetate or albumin. This finding contradicts with results of previous 
study after cardiac surgery, in which the use of gelatin was associated 
with lower need for allogenic blood transfusion than did use of HES 
(Van der Linden et al. 2004). 
     Neither the crystalloid nor the albumin solutions disturbed blood 
coagulation when used postoperatively, which is in agreement with 
previous findings. The clot strength in the Ringer’s acetate and albu-
min groups was significantly higher than in the HES or gelatin groups. 
Despite the slight changes in TEM, the postoperative bleeding was 
similar in all study groups. Several studies have demonstrated that the 
use of both modern HES and gelatin solutions is safe in regard to coa-
gulation. Because of the slight but negligible effect on blood coagula-
tion, however, the use of modern HES and gelatin solutions after car-
diac surgery must be considered carefully in those patients with he-
mostatic disturbances.  
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   Mechanisms of colloid-induced coagulopathy 
     Both HES and gelatin solutions can impair blood coagulation 
(Wilkes et al. 2001, Niemi and Kuitunen 2005). They interact with 
various coagulation factors, disturb fibrin meshing, and produce he-
modilution (Hiippala 1995, Petroianu et al. 2000, Boldt et al. 2002). 
The similar impairment of TEM with use of both InTEM and ExTEM 
reagents suggests that HES and gelatin affect both intrinsic and extrin-
sic coagulation pathways. They alter the strength of the whole blood 
clot (decreased MCF), and fibrin formation (prolonged CFT). There-
fore, contact activation of blood coagulation is inhibited by colloids, 
which may be important in the presence of heparin (i.e., during CPB 
or postoperatively when a residual effect of heparin is suspected). Af-
ter cardiac surgery, it is also very important to preserve tissue factor-
induced coagulation and minimize any risk for increased postoperative 
bleeding and reoperation. 
     The decreased MCF with FibTEM reagent demonstrates the im-
pairment of the fibrin component of clot strength, which is in accor-
dance with a previous study (Fenger-Eriksen et al. 2009). Therefore, 
the correction of colloid-promoted coagulopathy by fibrinogen is logi-
cal. This idea is also supported by the findings of the in vitro part of 
the present thesis (Study III). 
     No differences appeared in clot strength between ExTEM and Ap-
TEM reagents, which indicates an absence of abnormal fibrinolysis af-
ter the use of colloid solutions. Several studies have reported that both 
CPB and use of colloids per se may activate fibrinolysis (Nielsen 
2006), and use of antifibrinolytic drugs has been considered (Sedra-
kyan et al. 2006). The results of the present thesis do not support rou-
tine use of fibrinolysis inhibitors in patients undergoing elective car-
diac surgery. Furthermore, in one study, tranexamic acid had no effect 
on HES-induced coagulation disturbance after cardiac surgery (Kuitu-
nen et al. 2006). On the other hand, findings of this study could imply 
that TEM might be not sufficiently sensitive to show mild fibrinolysis.  
     This study demonstrated that the use of third generation HES, gela-
tin, albumin, and Ringer’s acetate solutions causes no changes in 
platelet MCF postoperatively. All the platelet MCF parameters were 
within the normal range. In this study, only those patients undergoing 
elective surgery were investigated. They had neither any coagulation 
disturbances nor medications which could elevate bleeding risk within 
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5 days prior to surgery. Preoperatively, platelet count was also within 
the normal range. On the other hand, CPB-induced platelet dysfunc-
tion can predispose patients to increased bleeding postoperatively. In 
the present study, neither modern HES nor gelatin altered platelet 
MCF, even after CPB, which is a very important property of colloid 
solution administered after cardiac surgery. The minimal effect of 
HES 130/0.38-0.45 on platelets has also been demonstrated (Franz et 
al. 2001).   
     The present thesis showed that the colloid solution gelatin impairs 
blood coagulation in vitro after 40 vol% hemodilution. The fibrinogen 
concentrate improved blood coagulation, as did FFP. Surprisingly, the 
effect of solely FVIII+vW and FXIII on coagulation impairment was 
minimal, which is in contrast to previous findings (Nielsen et al. 2004, 
Haas et al. 2008). Those in vitro studies investigated profound hemo-
dilution (up to 60%), at which point the activity of coagulation factors 
decreases dramatically. Therefore, the addition of single coagulation 
factors improved the quality of the clot. It is possible that after 40% 
hemodilution, which is closer to the clinical situation (i.e., during 
CPB), the amount of coagulation factors for the clotting process was 
sufficient, and the effect of administration of solely FVIII+vW and 
FXIII was minimal.  
 
Colloids and crystalloids after cardiac surgery: 
hemodynamics 
     This study demonstrated that the use of rapidly degradable HES 
solutions after elective cardiac surgery is an effective method to main-
tain postoperative hemodynamics, which is in agreement with pre-
vious findings (Gallandat Huet et al. 2000, Verheij et al. 2006a, Kui-
tunen et al. 2007). Many studies demonstrate the effectiveness of ra-
pidly degradable HES solutions, but discussion is continuous about 
the side-effects of these fluids. In the light of recent studies, the effect 
of HES 130/0.4 on renal function seems to be neutral (Mahmood et al. 
2007) even in those patients with renal failure (Boldt et al. 2007).   
     Despite its relatively low MW, third generation HES 130/0.4 is an 
effective plasma expander. In the present study, after the administra-
tion of HES solutions, CI and SVI increased significantly, even after a 
small dose of this fluid (7 mL kg
–1
), and this effect was greater than 
DISCUSSION 
 
 
55 
 
after use of gelatin, albumin, or Ringer’s acetate. The greatest effect of 
the single small dose of HES 130/0.4 (7 mL kg
–1
) could be explained 
by the MW of the HES molecule (130 kDa), which is more than four 
times as high as that of gelatin.  
     Surprisingly, this study showed that the effect of a single dose of 
gelatin solution (7 mL kg
–1
) on hemodynamics was comparable to that 
of Ringer’s acetate. This finding is novel. When gelatin was adminis-
tered repeatedly, its effect on CI and SVI was more pronounced and, 
at this stage, it was comparable with that of HES 130/0.4 (Van der 
Linden et al. 2004). After cardiac surgery, patients are usually over-
loaded with fluids (i.e., CPB priming, vasoactive agents, antibiotics). 
The power of the single small dose of HES 130/0.4 to raise the CI and 
SVI is therefore clinically very important.  
     Additionally, recent studies show that the side-effects of modern 
HES solutions on renal function, coagulation, and inflammation are 
comparable with those of the gelatin solution (Mahmood et al. 2007, 
Boldt et al. 2008). 
     The present thesis failed to demonstrate any difference in acid-base 
status postoperatively between the study groups. Only a slight increase 
in SID was observable after infusion of more than 14 mL kg
–1
 of gela-
tin solution (Study V), and this fact could be explained by the chloride 
amount’s being lower than with the HES or Ringer’s acetate solutions. 
On the other hand, both pH and BE remained unchanged in all the 
study groups. This slight increase in SID thus had no clinical relev-
ance, even along with a relative large dose of colloids (28 mL kg
–1
). 
 
Blood loss and fluid balance 
     The present thesis detected no difference in postoperative bleeding 
or fluid balance between groups on the first postoperative morning. 
The similar effect of HES 130/0.4 and gelatin on postoperative blood 
loss has already been demonstrated (Van der Linden et al. 2005). 
Moreover, the modern HES and gelatin solutions have been proven 
safe regarding bleeding in comparison with Ringer’s or albumin solu-
tions (Tigchelaar et al. 1997, Boldt et al. 2009). 
     The findings of a similar fluid balance diverge from those in an in-
vestigation (Tølløfsrud et al. 1995) claiming that a larger volume of 
DISCUSSION 
 
 
56 
 
crystalloids than of colloids is necessary to maintain hemodynamics 
(CI, PCWP, CVP). The Tølløfsrud group used colloids intraoperative-
ly, and fluid retention was greater in the crystalloid group only at the 
end of surgery, but not at 48 hours postoperatively. Unfortunately, the 
investigators did not report the fluid balance on the first postoperative 
morning. In the present study, a fixed similar dose of study solutions 
was administered. Therefore, it may have been the case that the fluid 
balance between these groups was comparable.  
 
Limitations of the study  
     As to limitations of the present study, it includes a relatively small 
number of patients undergoing different types of cardiac surgery. 
However, despite these differences, the patients experienced similar 
surgical trauma and received similar postoperative intensive care. All 
the procedures were performed through full median sternotomy using 
cannulation of the aorta and right atrium / vena cava. Therefore, the 
condition of these patients perioperatively can be considered compa-
rable. 
     Because of the small population and short observation time (first 
postoperative day), this study did not aim to detect differences in cli-
nical outcome. 
     The limitation of Study III is its lack of standardization of hemodi-
lution. The aim of this model was to achieve conditions that were, as 
far as possible, comparable to the real clinical situation during the ad-
ministration of FFP or specific coagulation factors in patients recei-
ving a colloid solution. Both in vivo with intact blood vessels and in 
vitro, administration of FFP inevitably results in a lower hematocrit 
than does the administration of single coagulation factors. 
     This study did not aim to detect differences in renal or other organ 
functions. However, in all groups, creatinine levels on the first post-
operative morning were similar.   
     In the present study, the same patient population took part in Stu-
dies I and IV, and Studies II and V. The major outcomes were, how-
ever, predetermined for each study individually, and the power was 
calculated for both MCF and CI in these studies. Therefore, it may be 
justified to report two clinically very important topics in separate stu-
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dies. The treatment of coagulation and hemodynamics was intraopera-
tively similar in all the patients. 
 
Clinical implications  
     In accordance with previous conclusions, the recommendation is to 
use the modern HES solutions for intravascular volume replacement 
in patients after elective cardiac surgery with preserved left ventricular 
function. HES 130/0.4 is the solution most effective hemodynamical-
ly, and any coagulation disturbances it caused were comparable with 
those of gelatin. However, the effect of a small single dose of gelatin 
on hemodynamics was significantly inferior to that of HES 130/0.4 
solution. 
     The use of fibrinogen or FFP, but not single coagulation factors 
(FVIII+vW and FXIII), is recommended for the treatment of colloid-
induced coagulopathy.  
     The use of modified TEM may improve the diagnostics of mechan-
isms of coagulation disturbances, and TEM is recommended to guide 
in the treatment of bleeding patients.  
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CONCLUSIONS 
 
     The present study showed that the effects of rapidly degradable 
HES and gelatin solutions on blood coagulation measured with TEM 
are similar. After elective cardiac surgery, the single small dose of 
HES 130/0.4 had a slightly greater effect on hemodynamics (CI and 
SVI) in comparison with gelatin. Specifically it was demonstrated that  
 
1. Modern HES and gelatin solutions impaired TEM, but the changes 
in blood coagulation did not elevate postoperative bleeding, based on 
similar postoperative chest tube drainage. The effect of the natural col-
loid 4% albumin and crystalloid Ringer’s acetate on blood coagulation 
was minimal. 
2. Neither HES nor gelatin impaired platelet function nor induced fi-
brinolysis after elective cardiac surgery.  
     Fibrinogen concentrate improved gelatin-induced coagulopathy in 
vitro, but effects of FVIII+vW and FXIII on coagulation changes de-
tected by TEM were minimal. 
3. A single dose of HES solution had a slightly greater immediate ef-
fect on CI and SVI than did gelatin, albumin, or Ringer’s acetate solu-
tions even at a small dose (7 mL kg
–1
). At this dose, the effect of gela-
tin solution on hemodynamics was lower than that of HES, and it was 
comparable to that of Ringer’s acetate. With repeated administration 
of gelatin at doses of 14 mL kg
–1
 or more, its effect on CI and SVI be-
gan to be comparable to that of HES 130/0.4. 
4. None of the study solutions changed acid-base equilibrium clinical-
ly significantly.  
     On the first postoperative morning, both hemodynamics and TEM 
parameters were similar in all the patients independent of the fluid 
used.  
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